Paul Roach

Department of Nuclear Medicien Royal North Shore Hospital St Leonards 2065 NSW

[ 1 ] - In Vivo Measurement and Characterization of a Novel Formulation of [177Lu]-DOTA-Octreotate

Objective(s):Lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as “No Carrier Added” (NCA) 177Lu. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate with NCA 177Lu (“NCA-LuTATE”) and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. In this paper, we report on...

[ 2 ] - Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System

Objective(s): Peptide Receptor Radionuclide Therapy (PRRT) with yttrium-90 (90Y) and lutetium-177 (177Lu)-labelled SST analogues are now therapy option for patients who have failed to respond to conventional medical therapy. In-house production with automated PRRT synthesis systems have clear advantages over manual methods resulting in increasing use in hospital-based radiopharmacies. We report...

نویسندگان همکار

Dale Bailey 2  

Alireza Aslani 1  

David Chan 1  

Eric Henry 1  

Kathy Willowson 1  

Thomas Hennessy 1  

Alireza Aslani 1  

Elizabeth Bailey 1  

Geoffrey Schembri 1  

Graeme Snowdon 1  

Pavlakis Nick 1